922 related articles for article (PubMed ID: 29786183)
1. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
2. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
3. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
4. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
5. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
6. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
7. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
Sarwar CMS; Bhagat AA; Anker SD; Butler J
Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
[TBL] [Abstract][Full Text] [Related]
8. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
10. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
11. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
[TBL] [Abstract][Full Text] [Related]
12. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
13. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
14. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI; Agarwal R
Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.
Hundemer GL; Sood MM
Pharmacol Res; 2021 Oct; 172():105835. PubMed ID: 34438065
[TBL] [Abstract][Full Text] [Related]
16. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
17. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
18. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
19. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
Tamargo M; Tamargo J
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):193-194. PubMed ID: 29982385
[No Abstract] [Full Text] [Related]
20. Treatment of Abnormalities of Potassium Homeostasis in CKD.
Palmer BF; Clegg DJ
Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]